1. Zimmermann J, Buchdunger E, Mett H, et al. Phenylaminopyrimidine (PAP)-derivatives: a new class of potent and highly selective PDGF receptor autophosphoryla-tion inhibitors. Biorg Chem Med Lett 1996; 6:1221-1226.
2. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105:3-7.
3. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105:2640 - 2653.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 1996; 2:561-566.
5. Deininger M, Goldman JM, Lydon NB, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997; 90:3691-3698.
6. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23:380-394.
7. Le Coutre P, Molgni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91:163-168.
8. Druker BJ, Talpaz M, Resta D, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037.
9. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-1042.
10. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-652.
11. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cyto-genetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928-1937.
12. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytoge-netic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99:3530-3539.
13. Sacchi S, Kantarjian H, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches in 162 patients. Cancer 1999; 86:2632 -2641.
14. Wadhwa J, Szydlo RM, Apperley JF, et al. Factors impacting on duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002; 99:2304-2309.
15. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
Sokal JE, Cox EB, Baccarani M, et al. and the Italian Cooperative CML Study Group. Prognostic discrimination in 'good risk' chronic granulocytic leukemia. Blood 1984; 63:789-799.
Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of imatinib therapy for newly diagnosed chronic myeloid leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med. In press.
Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-failure and in late CML-CP, comparison with historical controls. Clin Cancer Research 2004; 10:68-75.
Marin D, Marktel S, Szydlo R, et al. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure of interferon alfa. Lancet 2003; 362:617-619. Kantarjian H, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogen-ous leukemia in chronic phase. Comparison with historical data. Cancer 2003; 98:2636-2642.
Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versusinterferon alfa-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood Pre-published on line May 18, 2006.
Roy L, Guilhot J, Krahnke T, et al. Survival advantage with imatinib compared to the combination interferon-a plus cytarabine in chronic phase CML: historical comparison between two phase III trials. Blood. Pre-published on line April 20, 2006.
Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee of the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;
Goldman JM, Lu D.-P. Chronic granulocytic leukemia—origin, prognosis and treatment. Semin Hemat 1982; 19:241-256.
Gordon MY, Marley SB, Apperley JF, et al. Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons. Br J Haematol 2003; 122:424-429.
Sokal JE: Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment. Baillieres Clin Haematol 1987; 1:907-929.
Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95:738 - 743.
Huntly BJ, Reid AG, Bench AJ, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98:1732-1738. Huntly BJ, Guilhot F, Reid AG, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102:2205-2212.
Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005; 105:2281-2286. Yong ASM, Szydlo RM, Goldman JM, et al. Molecular profiling of CD34+ cells identifies low expression of CD7 along with high expression of proteinase 3 and elastase as predictors of longer survival in patients with CML. Blood 2006; 107:205-212. Ohmine K, Ota J, Ueda M, et al. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene 2001; 20:8249 - 8257.
Kaneta Y, Kagami Y, Katagiri T, et al. Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res 2002; 93:849-856.
Nowicki MO, Pawlowski P, Fischer T, et al. Chronic myelogenous leukemia molecular signature. Oncogene 2003, 22:3952-3963.
35. Radich J, Dai HD, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Nat Acad Sci USA 2006; 103:2794-2799.
36. Crossman LC, Mori M, Hsieh YC, et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 2005;90:459-464.
37. White D, Saunders V, Lyons AB, et al. In-vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in de-novo CML patients. Blood 2005; 106:2520-2526.
38. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101:2368-2373.
39. Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo JV. Analysis of total phospho-tyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood 2005; 105:4893 -4894.
40. Mahon F.-X, Belloc F, Cholet C, et al. Detection of resistance to STI571 in patients with BCR-ABL positive acute leukemia and chronic myeloid leukemia blast crisis (abstract). Blood 2000; 96:471a.
41. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is over-expressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood. Prepublished on line April 20, 2006.
42. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104:3739 - 3745.
43. Crossman LC, Druker BJ, Deininger MWN. hOCT1 and resistance to imatinib. Blood 2005; 106:1133-1134.
44. White DL, Saunders VA, Dang P, et al. OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107); reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. Prepublished on line April 4, 2006.
45. Goldman JM, Marin D. Management decisions in chronic myeloid leukemia. Semin Hematol 2003; 40:97-103.
46. Baccarani M, Saglio G, Goldman JM, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia-net. Blood. Prepublished on line. May 18, 2006.
47. Druker BJ, Gathmann I, Bolton A, et al. Probability and impact of obtaining a complete cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia (CML) in chronic phase (abstract). Blood 2003; 102:182a.
48. Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual disease and prognostic factors for cytogenetic relapse. Leukemia 2005; 19:507-512.
49. Goldman JM, Gordon MY. Why do stem CML cells survive allogeneic stem cell transplantation or imatinib? Does it really matter? Leukemia and Lymphoma 2006; 47:1-8 (Review).
50. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94:2056- 2064.
51. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99:319-325.
52. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate therapy. Blood 2003; 101:4701-4707.
53. Avery S, Nadal E, Marin D, et al. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. Leuk Res 2004; 28(suppl): S75-S77.
54. Jabbour E, Kantarjian H, O'Brien S, et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 2006; 107:480-482.
55. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104:2204-2205.
Merante S, Orlandi E, Bernasconi P, et al. Outcome for four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90:979 -981.
Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood. In press.
Drummond MW, Martin D, Clark RE, et al. Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Brit J Haematol 2003; 123:479-483. Bocchia M, Gentili S, Abruzzese E, et al. Effect of p210 multipeptide vaccine with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicenter observational trial. Lancet 2005; 365:657-662. Rojas JM, Knight K, Wang L, et al. Clinical evaluation of BCR-ABL peptide immunization in chronic myeloid leukemia: results of the EPIC study. Submitted for publication. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101:13,885-13,890.
Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6:1018-1023. Smith B, Kasamon YL, Miller CB, et al. K562/GM-CSF vaccination reduces tumor burden including achieving complete molecular remissions in chronic myeloid leukemia (CML) patients (PTS) with residual disease on imatinib mesylate (IM). J Clin Oncol 2006; 24(suppl 18S):339s (Abstract #6509).
Olavarria E, Craddock C, Dazzi F, et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99:3861-3862.
Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100:1590-1595.
Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 2005; 23:6316-6324.
Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic phase chronic myeloid leukemia. Blood 2004; 104:4243-4251.
Gardembas M, Rousselot P, Tulliez M, et al. Results of a prospective phase 2 study combining imatinib and cytarabine for the treatment of Philadelphia-positive patients with chronic myeloid leukemia in chronic phase. Blood 2003; 4298 -4305.
Issa J.-P, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005;
Hoover RR, Mahon FX, Melo JV, Daley QG. Overcoming STI resistance with with trans-feryl transferase inhibitor SCH66336. Blood 2002; 1068-1071.
Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003; 101:1692-1697.
Marin D, Kaeda J, Andreasson C, et al. Phase I/II trial of adding semisynthetic homohar-ringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005; 103:1850-1855.
Chen Y, Fan H, Pan X, et al. Coordination of intrinsic, extrinsic and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood 2006; 107:1582-1590.
Marin D, Marktel S, Bua M, et al. The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. Haematologica 2002; 87:979 -988. Deininger MWN, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21:1637-1647.
76. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004; 100:116-121.
77. Guilhot F. Indications for imatinib mesylate therapy and clinical management. The Oncologist 2004; 9:271-281.
78. Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylate induced hepato-toxicity in chronic myeloid leukemia demonstrated by focal necrosis resembling acute viral hepatitis. Leukemia 2002; 16:2160-2161.
79. Ebnoether M, Stentoft J, Ford J, et al. Cerebral oedema as a possible complication of treatment with iomatinib. Lancet 2002; 359:1751-1752.
80. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001; 98:2039-2042.
81. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with hyper-CVAD and imatinib mesylkate. Blood 2004; 103:4396-4407.
82. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia positive acute lymphoblastic leukemia (Ph + ALL). Blood. Pre-published on line April 25, 2006.
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.